In This Section

Bridging the Translational Gap in Ischemic Stroke Research

Tuesday April 09, 2019

2:00 pm - 3:30 pm Eastern Time (ET)

Room W206 B

CVP DDD NEU TCP

Chair :

Keith Pennypacker
University of Kentucky



Although ischemic stroke is one of the leading causes of death, researchers have failed to translate the success of preclinical studies into novel drugs for treating stroke patients. Some of the main reasons behind this failure to produce clinically relevant therapies include poor animal models, the failure to address the post-stroke immune response, insufficient transportation of drugs across the blood-brain barrier, and the failure to address white matter damage after stroke. Expert researchers will address each of these "problem areas" and provide solutions for future preclinical studies.

Speakers

Keith Pennypacker - University of Kentucky

Failure to Launch: Why Stroke Treatments Haven't Translated from Rodents to Humans

Stephanie Davis - University of Kentucky

Treatment with Leukemia Inhibitory Factor Alters Mitochondrial Function and Pro-Inflammatory Cytokine Expression in the Spleens of Aged Rats

Selva Baltan - Cleveland Clinic Lerner Research Institution

Regulating Mitochondrial Dynamics to Precondition and Promote Post-Ischemic Axon Function Recovery

Patrick Ronaldson - University of Arizona

Targeting the Blood-Brain Barrier for Delivery of Neuroprotective Drugs in Ischemic Stroke

Halina Offner - Oregon Health & Science University

Modulating the Adaptive Immune Response after Ischemic Stroke

Last Updated: August 15, 2019
Key Dates
April 6

ASPET Business Meeting and Awards Presentation

April 6-9

ASPET Annual Meeting at EB 2019